Clovis gains after FDA approves Rubraca

FDA granted accelerated approval to Rubraca rucaparib (CO-338) from Clovis Oncology Inc. (NASDAQ:CLVS) to treat women with advanced ovarian cancer who have received two or

Read the full 252 word article

User Sign In